FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2479777963> ?p ?o ?g. }

• W2479777963 abstract "Abstract Abstract 3128 Poster Board III-65 Enoxaparin (Lovenox®), fondaparinux (Arixtra®) and rivaroxaban (Xarelto®) have been shown to be effective in mediating antithrombotic effects in post-surgical indications. Because of marked differences in the pharmacokinetic and pharmacodynamic behavior of these drugs we hypothesized that after the last dosage, the duration of the residual antithrombotic activity of the various drugs also differs. In order to compare the duration of effect of these three drugs, a rabbit stasis-thrombosis model (RSTM) utilizing FEIBA as the thrombogenic challenge and a rabbit ear bleeding model (REBM) were employed. Individual groups of rabbits (n=5) were treated with doses to mimic prophylactic, therapeutic and supratherapeutic (5x therapeutic) drug levels. Enoxaparin and fondaparinux were administered subcutaneously and rivaroxaban was administered by oral gavage. Blood samples were collected at baseline and at 16-18 hours post-administration of the last dose on day 1 or after 4 days of repeated dosing in the RSTM or at 3 hours post-administration in the REBM. At the 16-18 hour time point, circulating anti-Xa levels were not observed in any of the treatment groups. Despite this, enoxaparin treated animals exhibited a strong antithrombotic response following administration of the therapeutic dose (clot score = 1.3 ± 0.6 vs. 2.7 ± 0.6 for saline controls). Dosing once daily for four days did not enhance the antithrombotic activity of enoxaparin. In the plasmatic thrombin generation assays, a reduction in thrombin generation was noted in samples from enoxaparin-treated animals. For enoxaparin, no increase in bleeding was observed at prophylactic or therapeutic doses when compared to saline. An increase in bleeding (∼5 fold vs. saline) was observed at 3 and 6 hours post-administration of the ‘overdose’. A dose-dependent increase in anti-Xa activity was observed in blood samples collected 3 hours post-administration. For fondaparinux, no increase in bleeding was observed with any of the doses tested. There was a moderate increase in anti-Xa activity in the samples from rabbits treated with the ‘overdose’ of fondaparinux. This level was comparable to that observed with the therapeutic dose of enoxaparin. These studies suggest that enoxaparin produces a sustained antithrombotic effect in contrast to rivaroxaban and fondaparinux. These observations underscore that residual/sustained antithrombotic effects of enoxaparin may be partly responsible for the prolonged antithrombotic actions associated with the clinical use of enoxaparin. Disclosures No relevant conflicts of interest to declare." @default.
• W2479777963 created "2016-08-23" @default.
• W2479777963 creator A5000190531 @default.
• W2479777963 creator A5007859032 @default.
• W2479777963 creator A5010173370 @default.
• W2479777963 creator A5030457785 @default.
• W2479777963 creator A5033914671 @default.
• W2479777963 creator A5069040417 @default.
• W2479777963 creator A5074304553 @default.
• W2479777963 creator A5080809634 @default.
• W2479777963 date "2009-11-20" @default.
• W2479777963 modified "2023-09-26" @default.
• W2479777963 title "Enoxaparin Produces Sustained Antithrombotic Effects in Comparison to Fondaparinux and Rivaroxaban: Clinical Implications." @default.
• W2479777963 doi "https://doi.org/10.1182/blood.v114.22.3128.3128" @default.
• W2479777963 hasPublicationYear "2009" @default.
• W2479777963 type Work @default.
• W2479777963 sameAs 2479777963 @default.
• W2479777963 citedByCount "0" @default.
• W2479777963 crossrefType "journal-article" @default.
• W2479777963 hasAuthorship W2479777963A5000190531 @default.
• W2479777963 hasAuthorship W2479777963A5007859032 @default.
• W2479777963 hasAuthorship W2479777963A5010173370 @default.
• W2479777963 hasAuthorship W2479777963A5030457785 @default.
• W2479777963 hasAuthorship W2479777963A5033914671 @default.
• W2479777963 hasAuthorship W2479777963A5069040417 @default.
• W2479777963 hasAuthorship W2479777963A5074304553 @default.
• W2479777963 hasAuthorship W2479777963A5080809634 @default.
• W2479777963 hasConcept C111113717 @default.
• W2479777963 hasConcept C112705442 @default.
• W2479777963 hasConcept C126322002 @default.
• W2479777963 hasConcept C141071460 @default.
• W2479777963 hasConcept C2776301958 @default.
• W2479777963 hasConcept C2776877702 @default.
• W2479777963 hasConcept C2776884760 @default.
• W2479777963 hasConcept C2777015399 @default.
• W2479777963 hasConcept C2777288759 @default.
• W2479777963 hasConcept C2777557582 @default.
• W2479777963 hasConcept C2778205648 @default.
• W2479777963 hasConcept C2778261982 @default.
• W2479777963 hasConcept C2778382381 @default.
• W2479777963 hasConcept C2778661090 @default.
• W2479777963 hasConcept C2778825682 @default.
• W2479777963 hasConcept C2779161974 @default.
• W2479777963 hasConcept C2780011451 @default.
• W2479777963 hasConcept C2780077467 @default.
• W2479777963 hasConcept C2780868729 @default.
• W2479777963 hasConcept C2909817843 @default.
• W2479777963 hasConcept C2991741193 @default.
• W2479777963 hasConcept C42219234 @default.
• W2479777963 hasConcept C71924100 @default.
• W2479777963 hasConcept C98274493 @default.
• W2479777963 hasConceptScore W2479777963C111113717 @default.
• W2479777963 hasConceptScore W2479777963C112705442 @default.
• W2479777963 hasConceptScore W2479777963C126322002 @default.
• W2479777963 hasConceptScore W2479777963C141071460 @default.
• W2479777963 hasConceptScore W2479777963C2776301958 @default.
• W2479777963 hasConceptScore W2479777963C2776877702 @default.
• W2479777963 hasConceptScore W2479777963C2776884760 @default.
• W2479777963 hasConceptScore W2479777963C2777015399 @default.
• W2479777963 hasConceptScore W2479777963C2777288759 @default.
• W2479777963 hasConceptScore W2479777963C2777557582 @default.
• W2479777963 hasConceptScore W2479777963C2778205648 @default.
• W2479777963 hasConceptScore W2479777963C2778261982 @default.
• W2479777963 hasConceptScore W2479777963C2778382381 @default.
• W2479777963 hasConceptScore W2479777963C2778661090 @default.
• W2479777963 hasConceptScore W2479777963C2778825682 @default.
• W2479777963 hasConceptScore W2479777963C2779161974 @default.
• W2479777963 hasConceptScore W2479777963C2780011451 @default.
• W2479777963 hasConceptScore W2479777963C2780077467 @default.
• W2479777963 hasConceptScore W2479777963C2780868729 @default.
• W2479777963 hasConceptScore W2479777963C2909817843 @default.
• W2479777963 hasConceptScore W2479777963C2991741193 @default.
• W2479777963 hasConceptScore W2479777963C42219234 @default.
• W2479777963 hasConceptScore W2479777963C71924100 @default.
• W2479777963 hasConceptScore W2479777963C98274493 @default.
• W2479777963 hasLocation W24797779631 @default.
• W2479777963 hasOpenAccess W2479777963 @default.
• W2479777963 hasPrimaryLocation W24797779631 @default.
• W2479777963 hasRelatedWork W144765624 @default.
• W2479777963 hasRelatedWork W1559864688 @default.
• W2479777963 hasRelatedWork W1668874089 @default.
• W2479777963 hasRelatedWork W1750582979 @default.
• W2479777963 hasRelatedWork W1755677376 @default.
• W2479777963 hasRelatedWork W1985080372 @default.
• W2479777963 hasRelatedWork W2056489010 @default.
• W2479777963 hasRelatedWork W2142041696 @default.
• W2479777963 hasRelatedWork W2158393936 @default.
• W2479777963 hasRelatedWork W2313350108 @default.
• W2479777963 hasRelatedWork W2339490821 @default.
• W2479777963 hasRelatedWork W2367758212 @default.
• W2479777963 hasRelatedWork W2410283220 @default.
• W2479777963 hasRelatedWork W2547679356 @default.
• W2479777963 hasRelatedWork W2562530087 @default.
• W2479777963 hasRelatedWork W2571701428 @default.
• W2479777963 hasRelatedWork W2573309397 @default.
• W2479777963 hasRelatedWork W2587972318 @default.
• W2479777963 hasRelatedWork W2888366179 @default.
• W2479777963 hasRelatedWork W3119359072 @default.
• W2479777963 isParatext "false" @default.
• W2479777963 isRetracted "false" @default.

• next